A legacy of innovation
Supernus Pharmaceuticals (sagerx.com) earns a Brand Analyzer score of 76 out of 100, placing it in the Brand-Ready tier among Healthcare brands. Among 4155 Healthcare brands analyzed, Supernus Pharmaceuticals ranks in the 61st percentile (category average 73, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 77/100, Digital Presence 100/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 94/100, AI Discoverability 43/100, Brand Authority 32/100.
Supernus Pharmaceuticals is a biopharmaceutical company headquartered in Rockville, United States, founded in 2005. It develops and delivers therapies for central nervous system (CNS) diseases, combining CNS disease expertise with strategic partnerships and acquisitions, such as Sage Therapeutics, to build its treatment portfolio. The company serves patients, healthcare providers, investors, and industry partners within the healthcare sector.
| Brand Name | Supernus Pharmaceuticals |
|---|---|
| Domain | sagerx.com |
| Industry | Healthcare |
| Founded | 2005 |
| Headquarters | Rockville |
| Main Competitors | Jazz Pharmaceuticals (82/100), Neurocrine Biosciences, Axsome Therapeutics (76/100), Harmony Biosciences (72/100), UCB (89/100), H. Lundbeck A/S |
Moz Domain Authority 55/100 vs category average 37 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,290,305 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Supernus, a biopharmaceutical company, develops CNS disease treatments. Transforming patient care with cutting-edge therapies and strategic partnerships." (Meta description: 17 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Drupal.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram, YouTube, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Supernus Pharmaceuticals scores 31/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Supernus Pharmaceuticals has a weak AI-visibility profile at 31/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (50/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,290,305 (Tranco) and a Moz Domain Authority of 55/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Supernus Pharmaceuticals's main competitors include Jazz Pharmaceuticals (82/100), Neurocrine Biosciences, Axsome Therapeutics, Harmony Biosciences (72/100), UCB (89/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Supernus Pharmaceuticals and UCB are competitors in Healthcare. Brand Analyzer scores Supernus Pharmaceuticals at 76/100 and UCB at 89/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Supernus Pharmaceuticals include Jazz Pharmaceuticals (82/100), Neurocrine Biosciences, Axsome Therapeutics, Harmony Biosciences (72/100), UCB (89/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Supernus Pharmaceuticals is a biopharmaceutical company based in Rockville, United States, founded in 2005. It focuses on developing and delivering treatments for central nervous system (CNS) diseases.
Supernus Pharmaceuticals has limited AI-search visibility, scoring 31/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 29, recommendation 50). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Supernus Pharmaceuticals was founded in 2005. Supernus Pharmaceuticals operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Supernus Pharmaceuticals is headquartered in Rockville. Supernus Pharmaceuticals operates in the Healthcare category.
Sources: Wikidata
Supernus Pharmaceuticals develops and delivers therapies aimed at treating central nervous system disorders. It builds its product portfolio through internal innovation as well as strategic partnerships and acquisitions, such as its acquisition of Sage Therapeutics.
Supernus Pharmaceuticals scores 50/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Supernus Pharmaceuticals can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Supernus Pharmaceuticals' offerings are used by patients suffering from central nervous system disorders, and the company engages with healthcare providers, investors, and pharmaceutical industry partners.
Supernus is known for its focus on CNS disease treatments and for expanding its therapeutic portfolio through strategic acquisitions, including its acquisition of Sage Therapeutics.
Ranked closest to Supernus Pharmaceuticals: Suvik Overseas Pvt. Ltd. (76/100), RocketDocs (76/100), Samaritan Ministries (76/100), ScionHealth (76/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zimmer Biomet (81/100).
Category leader: Elsevier (96/100).